Production (Stage)
Avidity Biosciences, Inc.
RNA
$30.58
-$0.23-0.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -61.46% | -51.87% | -38.69% | -30.47% | -19.01% |
| Total Depreciation and Amortization | 24.20% | 32.13% | 42.10% | 50.15% | 60.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.88% | 10.98% | 10.62% | 8.46% | 2.68% |
| Change in Net Operating Assets | -149.65% | -123.81% | 1,591.69% | 880.23% | 946.42% |
| Cash from Operations | -152.94% | -152.70% | -5.58% | 8.39% | 9.75% |
| Capital Expenditure | -198.04% | -67.12% | 4.79% | -1.48% | 14.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,908.33% | -573.17% | -298.01% | -98.78% | 117.54% |
| Cash from Investing | -2,121.32% | -556.72% | -291.25% | -96.67% | 115.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 152.51% | 1,019.66% | 249.81% | 110.51% | -7.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.11% | -- | -- | -- | -- |
| Cash from Financing | 74.83% | 1,170.30% | 296.08% | 151.47% | 33.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -160.87% | 124.01% | 594.85% | 1,372.59% | 1,795.67% |